Chronic Kidney Disease Market Forecast 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Statistics, Revenue, Therapies, Treatment, Companies by DelveInsight

(Albany, USA) Chronic Kidney Disease Summary
The Chronic Kidney Disease (CKD) therapeutics market in the US was valued at approximately USD 2,824 million in 2023 and is projected to grow throughout the forecast period. The US also reported the highest CKD prevalence among the 7MM, with around 40 million cases in 2023, anticipated to rise by 2034. In the same year, about 2 million males and 3 million females in the US were affected. Current CKD treatments-comprising ESAs, ACE inhibitors, ARBs, antidiabetics, SHPT therapies, and urate-lowering agents-collectively contributed to a market size of USD 5,479 million across the 7MM in 2023, expected to expand with upcoming therapeutic launches through 2034.

Notably, Boehringer Ingelheim's BI-690517, a novel selective aldosterone synthase inhibitor, demonstrated a 39.5% reduction in albuminuria over 14 weeks when combined with empagliflozin in a Phase II trial, marking the first study of this class atop standard care. These results, highlighted at ASN Kidney Week 2023, underscore the advancing treatment landscape. Additionally, Japan's CKD market stood at USD 1,402 million in 2023 and is anticipated to register robust growth by 2034.

DelveInsight's "Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Chronic Kidney Disease, historical and forecasted epidemiology as well as the Chronic Kidney Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Chronic Kidney Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Kidney Disease pipeline products will significantly revolutionize the Chronic Kidney Disease market dynamics.

To Know in detail about the Chronic Kidney Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Kidney Disease Market Forecast
https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key facts of the Chronic Kidney Disease Market Report:
• The Chronic Kidney Disease market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In March 2025, the FDA broadened the approval of Furoscix (furosemide injection) to include the treatment of edema in adults with chronic kidney disease (CKD), including those with nephrotic syndrome. The expanded indication, developed by scPharmaceuticals, Inc., is expected to become available by April 2025, following the agency's acceptance of the supplemental new drug application in July 2024.
• In January 2025, the FDA approved a new indication for semaglutide, allowing its use to reduce the risk of kidney disease progression, kidney failure, and cardiovascular death in adults with type 2 diabetes and CKD, as announced by Novo Nordisk.
• In November 2024, Unicycive Therapeutics (Nasdaq: UNCY) announced that the U.S. FDA has accepted its New Drug Application (NDA) for Oxylanthanum Carbonate (OLC), with a target action date of June 28, 2025, under the PDUFA. If approved, OLC has the potential to significantly enhance the treatment of hyperphosphatemia in Chronic Kidney Disease patients undergoing dialysis.
• In July 2024, Renalys Pharma has raised ¥6 billion ($3.8 million) in a Series A funding round to advance clinical trials for kidney disease treatments across Asia. The financing was led by Catalys Pacific and SR One, with additional support from a group of investors, including JPS Growth Investment Limited Partnership, Sumitomo Mitsui Trust Bank, Japan Co-Invest IV Limited Partnership, and NVCC No.9 Investment Limited Partnership.
• The Chronic Kidney Disease therapeutics market size in the US was approximately USD 2,824 million in 2023 and is expected to grow further during the forecast period.
• In 2023, the United Kingdom had the largest Chronic Kidney Disease market size among the EU countries, with nearly USD 421 million, while Italy recorded the smallest market size at approximately USD 132 million.
• The Chronic Kidney Disease therapeutics market size in Japan was estimated at around USD 1,402 million in 2023.
• According to DelveInsight's analysis, the total diagnosed prevalent cases of Chronic Kidney Disease in the 7MM were approximately 16 million in 2023.
• In 2023, the United States held the largest Chronic Kidney Disease market size among the 7MM, valued at around USD 2,824 million, with projections indicating further growth by 2034.
• In 2023, the United States reported the highest prevalence of Chronic Kidney Disease among the 7MM, with approximately 40 million cases, and this number is projected to grow by 2034.
• The Chronic Kidney Disease market in 2023, valued at USD 5,479 million across the 7MM, primarily consists of erythropoietin-stimulating agents (ESAs), ACE inhibitors, angiotensin receptor blockers (ARBs), antidiabetic medications, treatments for secondary hyperparathyroidism (SHPT), and urate-lowering therapies. The market is anticipated to expand further with the introduction of emerging therapies during the forecast period (2024-2034).
• In 2023, Japan's Chronic Kidney Disease market size was valued at USD 1,402 million, with projections indicating substantial growth at a notable CAGR by 2034.
• In 2023, the United Kingdom had the highest number of diagnosed prevalent cases of Chronic Kidney Disease among European countries, with around 2 million cases, followed by Germany with approximately 1 million cases. Italy, on the other hand, had the lowest prevalent population, totaling 731 thousand cases.
• In 2023, Japan reported nearly 3 million total diagnosed prevalent cases of Chronic Kidney Disease, representing about 22% of the total cases across the 7MM.
• DelveInsight's analysis shows that in the EU4 and the UK, more females are impacted than males, with approximately 3.55 million female cases and 3.4 million male cases in 2023.
• Key Chronic Kidney Disease Companies: ProKidney, Reata Pharmaceuticals, Inc., Novo Nordisk A/S, Boehringer Ingelheim, Eli Lilly and Company, KBP Biosciences, Kibow Pharma, Cincor Pharma, AstraZeneca, Allena Pharmaceuticals, DiaMedica Therapeutics Inc., Lexicon Pharmaceuticals, Sanofi, and others
• Chronic Kidney Disease Therapies: Ocedurenone (KBP-5074), BI 690517 + Empagliflozin, and others.
• The Chronic Kidney Disease epidemiology based on gender analyzed that Chronic Kidney Disease is slightly more common in women (14%) than men (12%)

Chronic Kidney Disease Overview
Chronic Kidney Disease (CKD) is a long-term condition characterized by a gradual loss of kidney function over time. The kidneys play a crucial role in filtering waste, toxins, and excess fluids from the blood. In CKD, this filtering ability is impaired, leading to a buildup of harmful substances in the body.
The condition is often caused by underlying health issues such as diabetes, high blood pressure, or glomerulonephritis. Symptoms may not appear until the disease is advanced and can include fatigue, swelling, nausea, and difficulty concentrating. Left untreated, CKD can progress to kidney failure, requiring dialysis or a kidney transplant. Early detection and management, including lifestyle changes and medications, can help slow disease progression.

Get a Free sample for the Chronic Kidney Disease Market Report:
https://www.delveinsight.com/report-store/chronic-kidney-disease-chronic-renal-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Chronic Kidney Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chronic Kidney Disease Epidemiology Segmentation:
The Chronic Kidney Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Chronic Kidney Disease
• Prevalent Cases of Chronic Kidney Disease by severity
• Gender-specific Prevalence of Chronic Kidney Disease
• Diagnosed Cases of Episodic and Chronic Chronic Kidney Disease

Download the report to understand which factors are driving Chronic Kidney Disease epidemiology trends @ Chronic Kidney Disease Epidemiology Forecast
https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Chronic Kidney Disease Epidemiology Segmentation:
The Chronic Kidney Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Chronic Kidney Disease
• Prevalent Cases of Chronic Kidney Disease by severity
• Gender-specific Prevalence of Chronic Kidney Disease
• Diagnosed Cases of Episodic and Chronic Chronic Kidney Disease

Chronic Kidney Disease Market
The dynamics of the Chronic Kidney Disease market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.
"Although the pipeline for the treatment of Chronic Kidney Disease looks robust, most of the investigational therapies aim at improving kidney function (measured by improved renal output), there are no curative therapies in development that aim to regain kidney function."

Chronic Kidney Disease Therapies and Key Companies
• TRC101 (Veverimer): Tricida
• Tolvaptan: Otsuka Pharmaceuticals
• AZD5718: AstraZeneca

To know more about Chronic Kidney Disease treatment, visit @ Chronic Kidney Disease Medications
https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Chronic Kidney Disease Market Drivers
• Rising Prevalence of CKD
• Advancements in Diagnostic Tools
• Development of Novel Therapies
• Increased Healthcare Spending
• Awareness Campaigns
• Favorable Regulatory Approvals

Chronic Kidney Disease Market Barriers
• High Treatment Costs
• Limited Access to Healthcare
• Late Diagnosis
• Side Effects of Therapies
• Regulatory Hurdles
• Patient Adherence Issues

Scope of the Chronic Kidney Disease Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Chronic Kidney Disease Companies: Tricida, Otsuka Pharmaceuticals, AstraZeneca, and others
• Key Chronic Kidney Disease Therapies: TRC101 (Veverimer), Tolvaptan, AZD5718, and others
• Chronic Kidney Disease Therapeutic Assessment: Chronic Kidney Disease current marketed and Chronic Kidney Disease emerging therapies
• Chronic Kidney Disease Market Dynamics: Chronic Kidney Disease market drivers and Chronic Kidney Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Chronic Kidney Disease Unmet Needs, KOL's views, Analyst's views, Chronic Kidney Disease Market Access and Reimbursement

Discover more about therapies set to grab major Chronic Kidney Disease market share @ Chronic Kidney Disease Treatment Landscape
https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Chronic Kidney Disease Market Report Introduction
2. Executive Summary for Chronic Kidney Disease
3. SWOT analysis of Chronic Kidney Disease
4. Chronic Kidney Disease Patient Share (%) Overview at a Glance
5. Chronic Kidney Disease Market Overview at a Glance
6. Chronic Kidney Disease Disease Background and Overview
7. Chronic Kidney Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Chronic Kidney Disease
9. Chronic Kidney Disease Current Treatment and Medical Practices
10. Chronic Kidney Disease Unmet Needs
11. Chronic Kidney Disease Emerging Therapies
12. Chronic Kidney Disease Market Outlook
13. Country-Wise Chronic Kidney Disease Market Analysis (2020-2034)
14. Chronic Kidney Disease Market Access and Reimbursement of Therapies
15. Chronic Kidney Disease Market Drivers
16. Chronic Kidney Disease Market Barriers
17. Chronic Kidney Disease Appendix
18. Chronic Kidney Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports
Chronic Kidney Disease Pipeline Insight
https://www.delveinsight.com/sample-request/chronic-kidney-disease-ckd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Chronic Kidney Disease Pipeline Insight provides comprehensive insights about the CKD pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the CKD companies, including AstraZeneca (LON: AZN), Eli Lilly and Company (NYSE: LLY), Shandong Suncadia Medicine, Boehringer Ingelheim, AdAlta (ASX: 1AD), Alebund Pharmaceuticals, SCOHIA PHARMA, DiaMedica Therapeutics (NASDAQ: DMAC), Roche (SWX: ROG), MC2 Therapeutics, Allena Pharmaceuticals (NASDAQ: ALNA), Regulus Therapeutics (NASDAQ: RGLS), UnicoCell Biomed (TPE: 6794), and Regeneron Pharmaceuticals (NASDAQ: REGN), among others.

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/ats-conference-coverage

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.